T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review.

Cardiovascular magnetic resonance provides insights into myocardial structure and function noninvasively, with high diagnostic accuracy and without ionizing radiation. Myocardial tissue characterization in particular gives cardiovascular magnetic resonance a prime role among all the noninvasive cardiovascular investigations. Late gadolinium enhancement imaging is an established method for visualizing replacement scar, providing diagnostic and prognostic information in a variety of cardiac conditions. Late gadolinium enhancement, however, relies on the regional segregation of tissue characteristics to generate the imaging contrast. Thus, myocardial pathology that is diffuse in nature and affecting the myocardium in a rather uniform and global distribution is not well visualized with late gadolinium enhancement. Examples include diffuse myocardial inflammation, fibrosis, hypertrophy, and infiltration. T1 mapping is a novel technique allowing to diagnose these diffuse conditions by measurement of T1 values, which directly correspond to variation in intrinsic myocardial tissue properties. In addition to providing clinically meaningful indices, T1-mapping measurements also allow for an estimation of extracellular space by calculation of extracellular volume fraction. Multiple lines of evidence suggest a central role for T1 mapping in detection of diffuse myocardial disease in early disease stages and complements late gadolinium enhancement in visualization of the regional changes in common advanced myocardial disease. As a quantifiable measure, it may allow grading of disease activity, monitoring progress, and guiding treatment, potentially as a fast contrast-free clinical application. We present an overview of clinically relevant technical aspects of acquisition and processing, and the current state of art and evidence, supporting its clinical use.

[1]  P. Lancellotti,et al.  [Update on myocarditis]. , 2018, Revue medicale de Liege.

[2]  H. Bezerra,et al.  T1 and T2 mapping for early diagnosis of dilated non-ischaemic cardiomyopathy in middle-aged patients and differentiation from normal physiological adaptation. , 2016, European heart journal cardiovascular Imaging.

[3]  Matthias Gutberlet,et al.  Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis: The MyoRacer-Trial. , 2016, Journal of the American College of Cardiology.

[4]  O. Rimoldi,et al.  From Left Ventricular Hypertrophy to Dysfunction and Failure. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[5]  Silvia Valbuena-López,et al.  Resonancia magnética cardiovascular en la práctica cardiológica: una guía concisa para la adquisición de imágenes y la interpretación clínica , 2016 .

[6]  V. Puntmann,et al.  Cardiovascular Magnetic Resonance in Cardiology Practice: A Concise Guide to Image Acquisition and Clinical Interpretation. , 2016, Revista espanola de cardiologia.

[7]  E. Nagel,et al.  Native T1 in deciphering the reversible myocardial inflammation in cardiac sarcoidosis with anti-inflammatory treatment. , 2016, International journal of cardiology.

[8]  M. Robson,et al.  Adenosine Stress and Rest T1 Mapping Can Differentiate Between Ischemic, Infarcted, Remote, and Normal Myocardium Without the Need for Gadolinium Contrast Agents , 2016, JACC. Cardiovascular imaging.

[9]  E. Nagel,et al.  T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. , 2016, JACC. Cardiovascular imaging.

[10]  E. Nagel,et al.  Is Myocardial Native T1 the One Answer for All? , 2016, JACC. Cardiovascular imaging.

[11]  A. Greiser,et al.  T1 Mapping by CMR Imaging: From Histological Validation to Clinical Implication. , 2016, JACC. Cardiovascular imaging.

[12]  E. Nagel,et al.  T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study. , 2015, Circulation Cardiovascular Imaging.

[13]  P. Kellman,et al.  Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage , 2015, Journal of the American Heart Association.

[14]  D. Berman,et al.  Native T1 Mapping by 3-T CMR Imaging for Characterization of Chronic Myocardial Infarctions. , 2015, JACC. Cardiovascular imaging.

[15]  M. Caulfield,et al.  Extracellular volume quantification in isolated hypertension - changes at the detectable limits? , 2015, Journal of Cardiovascular Magnetic Resonance.

[16]  Eike Nagel,et al.  T1 mapping in myocarditis – headway to a new era for cardiovascular magnetic resonance , 2015, Expert review of cardiovascular therapy.

[17]  M. Horsfield,et al.  Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. , 2015, European heart journal cardiovascular Imaging.

[18]  B. Gerber,et al.  Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T , 2015, Journal of Cardiovascular Magnetic Resonance.

[19]  S. K. White,et al.  Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload , 2015, Journal of magnetic resonance imaging : JMRI.

[20]  B. Schnackenburg,et al.  Performance of T1 and T2 Mapping Cardiovascular Magnetic Resonance to Detect Active Myocarditis in Patients With Recent-Onset Heart Failure , 2015, Circulation. Cardiovascular imaging.

[21]  S. Plein,et al.  The effect of changes to MOLLI scheme on T1 mapping and extra cellular volume calculation in healthy volunteers with 3 tesla cardiovascular magnetic resonance imaging. , 2015, Quantitative imaging in medicine and surgery.

[22]  P. Matthews,et al.  Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping. , 2015, JACC. Cardiovascular imaging.

[23]  J. Zamorano,et al.  Imaging in HF-PEF with Cardiovascular Magnetic Resonance , 2015, Current Cardiovascular Imaging Reports.

[24]  Yong-Jin Kim,et al.  Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. , 2015, Radiology.

[25]  G. Korosoglou,et al.  T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. , 2015, European heart journal cardiovascular Imaging.

[26]  F. Epstein,et al.  Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. , 2015, JACC. Cardiovascular imaging.

[27]  S. Plein,et al.  Single bolus versus split dose gadolinium administration in extra-cellular volume calculation at 3 Tesla , 2015, Journal of Cardiovascular Magnetic Resonance.

[28]  S. Piechnik,et al.  T1 mapping and survival in systemic light-chain amyloidosis , 2014, European heart journal.

[29]  Christoph Tillmanns,et al.  Guía de práctica clínica de la ESC 2014 sobre el diagnóstico y manejo de la miocardiopatía hipertrófica , 2015 .

[30]  D. Kaye,et al.  Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. , 2015, European heart journal cardiovascular Imaging.

[31]  M. Mayr,et al.  Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. , 2015, JACC. Cardiovascular imaging.

[32]  T. Ebbers,et al.  Simultaneous three-dimensional myocardial T1 and T2 mapping in one breath hold with 3D-QALAS , 2014, Journal of Cardiovascular Magnetic Resonance.

[33]  S. K. White,et al.  Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance , 2014, Journal of Cardiovascular Magnetic Resonance.

[34]  Martin Borggrefe,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[35]  V. Puntmann,et al.  T1 mapping - beware regional variations. , 2014, European heart journal cardiovascular Imaging.

[36]  David M Higgins,et al.  Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study , 2014, Journal of Cardiovascular Magnetic Resonance.

[37]  L. Ling,et al.  A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype. , 2014, European heart journal cardiovascular Imaging.

[38]  E. Nagel,et al.  Aortic Stiffness and Interstitial Myocardial Fibrosis by Native T1 Are Independently Associated With Left Ventricular Remodeling in Patients With Dilated Cardiomyopathy , 2014, Hypertension.

[39]  E. Cook,et al.  Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy , 2014, Circulation.

[40]  B. Schnackenburg,et al.  CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging. , 2014, JACC. Cardiovascular imaging.

[41]  T. Marwick,et al.  Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. , 2014, European heart journal cardiovascular Imaging.

[42]  Richard B Thompson,et al.  Saturation recovery single‐shot acquisition (SASHA) for myocardial T1 mapping , 2014, Magnetic resonance in medicine.

[43]  S. Colan,et al.  Myocardial extracellular remodeling is associated with ventricular diastolic dysfunction in children and young adults with congenital aortic stenosis. , 2014, Journal of the American College of Cardiology.

[44]  René M. Botnar,et al.  Individualized cardiovascular risk assessment by cardiovascular magnetic resonance. , 2014, Future cardiology.

[45]  A. van Rossum,et al.  In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy , 2014, Journal of Cardiovascular Magnetic Resonance.

[46]  Richard B. Thompson,et al.  Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. , 2014, Radiology.

[47]  L. Kuller,et al.  Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. , 2014, European heart journal.

[48]  P. Matthews,et al.  Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis – a clinical study using myocardial T1-mapping and extracellular volume quantification , 2014, Journal of Cardiovascular Magnetic Resonance.

[49]  D. Stub,et al.  Diffuse myocardial fibrosis evaluated by post-contrast t1 mapping correlates with left ventricular stiffness. , 2014, Journal of the American College of Cardiology.

[50]  S. K. White,et al.  Native T1 mapping in transthyretin amyloidosis. , 2014, JACC. Cardiovascular imaging.

[51]  P. Matthews,et al.  Diffuse myocardial fibrosis is associated with impaired myocardial strain and disease activity in rheumatoid arthritis: a cardiovascular magnetic resonance study , 2014, Journal of Cardiovascular Magnetic Resonance.

[52]  J. Moon,et al.  Review of T1 Mapping Methods: Comparative Effectiveness Including Reproducibility Issues , 2014, Current Cardiovascular Imaging Reports.

[53]  P. Kellman,et al.  T1-mapping in the heart: accuracy and precision , 2014, Journal of Cardiovascular Magnetic Resonance.

[54]  P. Weale,et al.  Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis , 2013, European heart journal cardiovascular Imaging.

[55]  V. Fuster,et al.  The MOGE(S) Classification for a Phenotype-Genotype Nomenclature of Cardiomyopathy: Endorsed by the World Heart Federation. , 2013, Global heart.

[56]  C. Kramer,et al.  Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T1 mapping , 2013, Journal of magnetic resonance imaging : JMRI.

[57]  G. Maurer,et al.  Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection Fraction , 2013, Circulation. Cardiovascular imaging.

[58]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[59]  M. Robson,et al.  Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement , 2013, Journal of Cardiovascular Magnetic Resonance.

[60]  Stefan Neubauer,et al.  T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. , 2013, JACC. Cardiovascular imaging.

[61]  Chia-Ying Liu,et al.  Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). , 2013, Journal of the American College of Cardiology.

[62]  Tobias Schaeffter,et al.  Standardization of T1 measurements with MOLLI in differentiation between health and disease – the ConSept study , 2013, Journal of Cardiovascular Magnetic Resonance.

[63]  A. Didangelos,et al.  Extracellular Matrix Secretion by Cardiac Fibroblasts: Role of MicroRNA-29b and MicroRNA-30c , 2013, Circulation research.

[64]  Stefan Neubauer,et al.  T1 measurements in the human myocardium: The effects of magnetization transfer on the SASHA and MOLLI sequences , 2013, Magnetic resonance in medicine.

[65]  W. Stevenson,et al.  CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. , 2013, JACC. Cardiovascular imaging.

[66]  M. Robson,et al.  T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. , 2013, JACC. Cardiovascular imaging.

[67]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[68]  Joseph A. Hill,et al.  Pathological Ventricular Remodeling: Therapies Part 2 of 2 , 2013, Circulation.

[69]  S. Piechnik,et al.  Comprehensive Cardiac Magnetic Resonance Imaging and Spectroscopy Reveal a High Burden of Myocardial Disease in HIV Patients , 2013, Circulation.

[70]  F. Epstein,et al.  Comparison of methods for determining the partition coefficient of gadolinium in the myocardium using T1 mapping , 2013, Journal of magnetic resonance imaging : JMRI.

[71]  P. Kellman,et al.  T1 and extracellular volume mapping in the heart: estimation of error maps and the influence of noise on precision , 2013, Journal of Cardiovascular Magnetic Resonance.

[72]  Thoralf Niendorf,et al.  Myocardial T1 and T2 mapping at 3 T: reference values, influencing factors and implications , 2013, Journal of Cardiovascular Magnetic Resonance.

[73]  Richard B. Thompson,et al.  Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling , 2013, Journal of Cardiovascular Magnetic Resonance.

[74]  M. Robson,et al.  Diagnostic value of pre-contrast T1 mapping in acute and chronic myocardial infarction. , 2013, JACC. Cardiovascular imaging.

[75]  Karl Swedberg,et al.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.

[76]  R. Kwong,et al.  T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy , 2013, Circulation. Cardiovascular imaging.

[77]  Andrew S Flett,et al.  Comprehensive Validation of Cardiovascular Magnetic Resonance Techniques for the Assessment of Myocardial Extracellular Volume , 2013, Circulation. Cardiovascular imaging.

[78]  S. K. White,et al.  Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping , 2013, Circulation. Cardiovascular imaging.

[79]  M. Robson,et al.  Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. , 2013, JACC. Cardiovascular imaging.

[80]  Reza Razavi,et al.  Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. , 2013, JACC. Cardiovascular imaging.

[81]  B. Lindsay,et al.  ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, Ameri , 2013, Heart rhythm.

[82]  B. Lindsay,et al.  ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, Ameri , 2013, Journal of the American College of Cardiology.

[83]  Tevfik F Ismail,et al.  Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. , 2013, JAMA.

[84]  E. Nagel,et al.  Native Myocardial T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Subclinical Cardiomyopathy in Patients With Systemic Lupus Erythematosus , 2013, Circulation. Cardiovascular imaging.

[85]  Andrew S Flett,et al.  Human non-contrast T1 values and correlation with histology in diffuse fibrosis , 2013, Heart.

[86]  S. K. White,et al.  Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI , 2013, Journal of Cardiovascular Magnetic Resonance.

[87]  A. Flett,et al.  Quantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis: An Equilibrium Contrast Cardiovascular Magnetic Resonance Study , 2013, Circulation. Cardiovascular imaging.

[88]  Michael Jerosch-Herold,et al.  Role of Transcytolemmal Water-Exchange in Magnetic Resonance Measurements of Diffuse Myocardial Fibrosis in Hypertensive Heart Disease , 2013, Circulation. Cardiovascular imaging.

[89]  Ivan C. Gerling,et al.  Myofibroblast-mediated mechanisms of pathological remodelling of the heart , 2013, Nature Reviews Cardiology.

[90]  Andrew S Flett,et al.  Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR , 2012, Journal of Cardiovascular Magnetic Resonance.

[91]  James O. Mudd,et al.  T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. , 2012, Radiology.

[92]  Stefan Neubauer,et al.  Myocardial Tissue Characterization Using Magnetic Resonance Noncontrast T1 Mapping in Hypertrophic and Dilated Cardiomyopathy , 2012, Circulation. Cardiovascular imaging.

[93]  Andrew J Taylor,et al.  Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction , 2012, Journal of Cardiovascular Magnetic Resonance.

[94]  L. Mulligan,et al.  Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. , 2012, Journal of the American College of Cardiology.

[95]  E. Nagel,et al.  Design and rationale of the MR-INFORM study: stress perfusion cardiovascular magnetic resonance imaging to guide the management of patients with stable coronary artery disease , 2012, Journal of Cardiovascular Magnetic Resonance.

[96]  P. Kellman,et al.  Association Between Extracellular Matrix Expansion Quantified by Cardiovascular Magnetic Resonance and Short-Term Mortality , 2012, Circulation.

[97]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[98]  M. Robson,et al.  Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance , 2012, Journal of Cardiovascular Magnetic Resonance.

[99]  Marie-Pierre Jolly,et al.  Motion correction for myocardial T1 mapping using image registration with synthetic image estimation , 2012, Magnetic resonance in medicine.

[100]  G. Schuler,et al.  Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. , 2012, JACC. Cardiovascular imaging.

[101]  K. Klingel,et al.  Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. , 2012, Journal of the American College of Cardiology.

[102]  P. Kellman,et al.  Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. , 2012, European heart journal.

[103]  David A Bluemke,et al.  T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA , 2012, Journal of Cardiovascular Magnetic Resonance.

[104]  Theodore P Abraham,et al.  The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance , 2012, Journal of Cardiovascular Magnetic Resonance.

[105]  M. Robson,et al.  Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction , 2012, Journal of Cardiovascular Magnetic Resonance.

[106]  R. Kwong,et al.  Left ventricular mass by cardiac magnetic resonance imaging and adverse cardiovascular outcomes in patients treated with anthracycline-based chemotherapy , 2012, Journal of Cardiovascular Magnetic Resonance.

[107]  J. Ridgway,et al.  Cardiovascular magnetic resonance physics for clinicians: part II , 2010, Journal of Cardiovascular Magnetic Resonance.

[108]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[109]  Peter Kellman,et al.  Myocardial T1 and extracellular volume fraction mapping at 3 tesla , 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[110]  P. Poole‐Wilson,et al.  Role of Cardiovascular Magnetic Resonance as a Gatekeeper to Invasive Coronary Angiography in Patients Presenting With Heart Failure of Unknown Etiology , 2011, Circulation.

[111]  Pierre Croisille,et al.  Assessment of myocardial fibrosis with cardiovascular magnetic resonance. , 2011, Journal of the American College of Cardiology.

[112]  P. Kistler,et al.  Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. , 2011, Journal of the American College of Cardiology.

[113]  M. Cheitlin,et al.  Myocardial Scar Visualized by Cardiovascular Magnetic Resonance Imaging Predicts Major Adverse Events in Patients With Hypertrophic Cardiomyopathy , 2011 .

[114]  J. Ridgway Cardiovascular magnetic resonance physics for clinicians: part I , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[115]  Stefan Neubauer,et al.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[116]  Michael Jerosch-Herold,et al.  Quantification of Diffuse Myocardial Fibrosis and Its Association With Myocardial Dysfunction in Congenital Heart Disease , 2010, Circulation. Cardiovascular imaging.

[117]  S. Colan,et al.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. , 2010, The New England journal of medicine.

[118]  M. Hayward,et al.  Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis: Preliminary Validation in Humans , 2010, Circulation.

[119]  U. Siebert,et al.  Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. , 2009, The New England journal of medicine.

[120]  R. Kim,et al.  Detection of Myocardial Damage in Patients With Sarcoidosis , 2009, Circulation.

[121]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .

[122]  J. Schulz-Menger,et al.  Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. , 2009, Journal of the American College of Cardiology.

[123]  Sandeep N. Gupta,et al.  Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. , 2008, Journal of the American College of Cardiology.

[124]  D. Pennell,et al.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. , 2008, European heart journal.

[125]  E. Olson,et al.  Cardiac plasticity. , 2008, The New England journal of medicine.

[126]  James A. White,et al.  The role of cardiovascular MRI in heart failure and the cardiomyopathies. , 2007, Magnetic resonance imaging clinics of North America.

[127]  S. Plein,et al.  Myocardial T1 mapping: Application to patients with acute and chronic myocardial infarction , 2007, Magnetic resonance in medicine.

[128]  G. Dorn The Fuzzy Logic of Physiological Cardiac Hypertrophy , 2007, Hypertension.

[129]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[130]  David M Higgins,et al.  Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution--reproducibility study. , 2006, Radiology.

[131]  David M Higgins,et al.  T1 measurement using a short acquisition period for quantitative cardiac applications. , 2005, Medical physics.

[132]  R. Falk,et al.  Cardiovascular magnetic resonance in cardiac amyloidosis. , 2005, Circulation.

[133]  David M Higgins,et al.  Modified Look‐Locker inversion recovery (MOLLI) for high‐resolution T1 mapping of the heart , 2004, Magnetic resonance in medicine.

[134]  Udo Sechtem,et al.  Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology , 2004, Circulation.

[135]  C H Lorenz,et al.  Differentiation of Heart Failure Related to Dilated Cardiomyopathy and Coronary Artery Disease Using Gadolinium‐Enhanced Cardiovascular Magnetic Resonance , 2003, Circulation.

[136]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[137]  N. Sharpe,et al.  Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. , 2000, Circulation.

[138]  N. Rafique Hypertensive heart disease. , 1993, JPMA. The Journal of the Pakistan Medical Association.

[139]  D. Look,et al.  Time Saving in Measurement of NMR and EPR Relaxation Times , 1970 .

[140]  E. Nagel,et al.  Mapping in Discrimination of Hypertrophic Phenotypes : Hypertensive Heart Disease and Hypertrophic Cardiomyopathy Findings From the International T 1 Multicenter Cardiovascular Magnetic Resonance Study , 2022 .